A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma.

4121 Background: TG01 targets oncogenic mutations in RAS genes that are present in 80-90% of pancreatic cancers. TG01 is a mixture of 7 RAS peptides and previously, as monotherapy in patients with ...